SCHEMBL6877847

SCHEMBL6877847

COc1ccc2c(O)cc(OCC(F)(F)F)nc2c1C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.36
HPGD P15428 1/20 0.36
HSD17B10 Q99714 1/20 0.36
IDO1 P14902 1/20 0.36
TDO2 P48775 1/20 0.36
PDE10A Q9Y233 2/20 0.35
PDE4B Q07343 4/20 0.35
ATP1A1 P05023 1/20 0.34
ATP1B1 P05026 1/20 0.34
ATP1A3 P13637 1/20 0.34
ATP1B2 P14415 1/20 0.34
ATP4A P20648 1/20 0.34
ATP1A2 P50993 1/20 0.34
ATP4B P51164 1/20 0.34
ATP1B3 P54709 1/20 0.34
FXYD2 P54710 1/20 0.34
ATP1A4 Q13733 1/20 0.34
PTGS1 P23219 1/20 0.34
PTGS2 P35354 1/20 0.34
SCN9A Q15858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1952047 0.84 USP2 (0.39) ALDH1A1PDE4BTUBB1
SCHEMBL6879591 0.79 CSF1R (0.43) ALDH1A1HPGDPTGS1PTGS2
SCHEMBL6875131 0.76 MAPT (0.40) ALDH1A1HPGDHSD17B10PDE10APDE4B
SCHEMBL3370734 0.76 ESR1 (0.40) ALDH1A1HPGDHSD17B10PDE4B
SCHEMBL6877381 0.74 PDGFRB (0.36) PDE4B
SCHEMBL13763617 0.74 PTGS1 (0.40) ALDH1A1HPGDHSD17B10PDE4BATP1A1
SCHEMBL313117 0.73 NPC1 (0.37) ALDH1A1HPGDHSD17B10PDE10APDE4B
SCHEMBL3372000 0.73 MAP4K4 (0.37) ALDH1A1HPGDSCN9ACYP1A2
SCHEMBL6877498 0.72 PDGFRB (0.40) PDE4B
SCHEMBL15216114 0.72 GAA (0.38) ALDH1A1HPGDHSD17B10IDO1TDO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120077737-A1 HEPATITIS C INHIBITOR COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-03-29 US disclosed
US-20120077737-A1 HEPATITIS C INHIBITOR COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-03-29 US disclosed
US-20110294778-A1 HEPATITIS C INHIBITOR COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-12-01 US disclosed
US-20110294778-A1 HEPATITIS C INHIBITOR COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-12-01 US disclosed
WO-2011063502-A1 HEPATITIS C INHIBITOR COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-06-03 WO disclosed
WO-2011063501-A1 HEPATITIS C INHIBITOR COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110294778-A1 HEPATITIS C INHIBITOR COMPOUNDS ABCC1, CTRC, HAVCR2 ALDH1A1 566/4885HPGD 2579/4885HSD17B10 664/4885
US-20120077737-A1 HEPATITIS C INHIBITOR COMPOUNDS CTSC, HCCS, CTSZ ALDH1A1 2519/4885HPGD 3766/4885HSD17B10 644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.